List of Excipients in Branded Drug UP AND UP ARTHRITIS PAIN RELIEF

« Back to Dashboard

Generic Drugs Containing UP AND UP ARTHRITIS PAIN RELIEF

Company	Ingredient	NDC	Excipient
Target Corporation	acetaminophen	11673-210	CARNAUBA WAX
Target Corporation	acetaminophen	11673-210	CELLULOSE, MICROCRYSTALLINE
Target Corporation	acetaminophen	11673-210	CROSCARMELLOSE SODIUM
Target Corporation	acetaminophen	11673-210	HYPROMELLOSES
Target Corporation	acetaminophen	11673-210	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in UP AND UP ARTHRITIS PAIN RELIEF?

# Of NDCs	Excipient
1	CARNAUBA WAX
1	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
1	HYPROMELLOSES
1	MAGNESIUM STEARATE

UP AND UP Arthritis Pain Relief: Excipient Strategy and Commercial Opportunities

Last updated: September 27, 2026

Up&up Arthritis Pain Relief is a private-label extended-release acetaminophen product positioned against Tylenol 8 HR Arthritis Pain. Its commercial value comes from low-cost, high-throughput tablet manufacture, an eight-hour dosing claim, and retail substitution rather than novel active-ingredient protection. The principal excipient opportunities are controlled release, swallowability, tablet robustness, coating performance, packaging stability, and line extensions.

The product is generally identified as acetaminophen extended-release caplets containing 650 mg acetaminophen per caplet. The applicable U.S. regulatory framework is the FDA OTC monograph for internal analgesic, antipyretic, and antirheumatic drug products, rather than a new-drug approval pathway.[1][2]

What is Up&Up Arthritis Pain Relief?

Up&up Arthritis Pain Relief is a Target private-label OTC analgesic. The product is designed for temporary relief of minor arthritis pain and other minor aches and pains. The active ingredient is acetaminophen, also known as paracetamol, at an extended-release strength of 650 mg per caplet.[2]

Attribute	Product profile
Brand	Up&up
Retailer	Target
Product category	OTC arthritis pain reliever
Active ingredient	Acetaminophen
Strength	650 mg per caplet
Dosage form	Extended-release caplet
Primary use	Temporary relief of minor arthritis pain
Reference competition	Tylenol 8 HR Arthritis Pain
Regulatory route	OTC monograph
Orange Book status	Generally not expected to have an Orange Book listing as a monograph OTC product
Primary commercial lever	Retail price and private-label substitution
Key technical lever	Release control without dose dumping

The product competes in a mature category with limited active-ingredient differentiation. Product performance depends on dissolution behavior, tablet size, ease of swallowing, stability, packaging, and consumer trust.

What excipients are used in Up&Up Arthritis Pain Relief?

Public product labeling identifies excipients used in the caplet formulation, although the precise quantitative composition and manufacturing process are generally not disclosed. The formulation is expected to use standard tablet excipients associated with extended-release acetaminophen products.

Potential functional excipient classes include:

Excipient class	Typical function in an extended-release acetaminophen caplet
Hypromellose	Hydrophilic matrix former and release-controlling polymer
Microcrystalline cellulose or related cellulose material	Diluent, compressibility aid, and structural support
Corn starch or pregelatinized starch	Binder, filler, or disintegration aid
Sodium starch glycolate	Disintegration support where used
Povidone	Binder and granulation aid
Magnesium stearate	Lubricant
Carnauba wax or similar wax	Surface protection, gloss, or release modification
Film-coating polymers	Appearance, swallowability, moisture protection, and branding
Colorants	Product identification and consumer differentiation

The functional architecture is likely a matrix-based extended-release tablet. Hypromellose hydrates after ingestion and forms a viscous gel layer. Drug diffusion and gradual matrix erosion control acetaminophen release. The formulation must maintain release over the labeled dosing interval while avoiding excessive early release or incomplete drug release.

The exact inactive-ingredient list should be taken from the current package label for the specific SKU and market. Private-label products can change suppliers, excipient grades, coatings, and manufacturing sites without changing the commercial product name.

How does the excipient strategy control acetaminophen release?

Extended-release acetaminophen presents a formulation challenge because the dose is high relative to tablet mass. The formulation must combine a large amount of active ingredient with sufficient polymer and mechanical structure to produce reproducible release.

Hydrophilic matrix design

A hydrophilic polymer such as hypromellose is the principal release-control tool. Polymer viscosity grade, particle size, substitution type, concentration, and distribution within the tablet can change dissolution behavior.

A higher-viscosity polymer generally produces a stronger gel barrier and slower release. A lower-viscosity grade may improve manufacturability and reduce tablet size but can increase early drug release. Polymer concentration also affects tablet hardness, hydration, erosion, and residual drug release.

Compression and porosity

Compression force changes tablet porosity and liquid penetration. Higher compression can slow hydration and reduce initial release but may increase capping, lamination, or manufacturing stress. Excessively dense tablets can produce unacceptable residual drug levels at later dissolution time points.

Granulation method is also important. Direct compression can lower manufacturing cost but may create segregation and flow challenges when the formulation contains a large acetaminophen load. Wet granulation can improve content uniformity and compactability but adds process complexity, drying requirements, and potential stability risks.

Release-profile control

A commercially viable formulation should be evaluated across:

• Initial release or dose-dumping risk
• Midpoint release consistency
• Complete release within the labeled testing window
• Sensitivity to agitation and hydrodynamic conditions
• Alcohol-induced release changes
• Tablet-to-tablet variability
• Performance after packaging and storage

Alcohol-triggered dose dumping is a specific risk for modified-release oral products. Formulators should test multiple ethanol concentrations and exposure conditions, even where the product’s regulatory path does not require the same development package as an NDA product.

What formulation improvements create commercial opportunities?

The strongest opportunities involve consumer usability and manufacturing economics rather than a new analgesic mechanism.

Smaller or easier-to-swallow caplets

A 650 mg acetaminophen dose creates a large tablet burden. A smaller caplet could improve adherence, particularly among older adults with arthritis and dysphagia. Size reduction may require higher-density excipients, improved granulation, or a bilayer configuration.

Potential approaches include:

• Higher-compressibility cellulose grades
• Co-processed excipients
• More efficient polymer distribution
• Bilayer or multilayer compression
• Film coatings with lower weight gain
• Caplet geometry optimization

Any size reduction must preserve dose uniformity, mechanical strength, dissolution performance, and label compliance.

Improved swallowability

Low-friction film coatings can reduce swallowing difficulty without materially changing release. A smooth, low-tack coating may be commercially attractive for an arthritis population, especially where hand mobility and dexterity limit access to tablets.

Potential differentiators include:

• High-slip film coatings
• Reduced tablet edge roughness
• Improved caplet curvature
• Color and imprint contrast
• Lower tablet friability
• Easy-open packaging paired with senior-friendly handling

Lower-cost manufacturing

Excipients with better flow and compactability can reduce granulation time, compression defects, tooling wear, and batch rejects. A co-processed filler-binder may reduce the number of individual excipients and simplify raw-material management.

The commercial benefit is largest in private-label products because retail price pressure is high and gross margin depends heavily on conversion cost, packaging, logistics, and retailer terms.

Moisture and stability protection

Acetaminophen is generally stable under appropriate conditions, but excipient moisture, coating permeability, and packaging selection affect long-term performance. Moisture-sensitive tablet components may require:

• High-barrier blister packaging
• Induction-sealed bottles
• Desiccant systems
• Low-moisture excipient grades
• Improved coating systems
• Tighter residual-moisture controls

Packaging can be a more efficient stability intervention than changing the tablet formulation. The trade-off is higher packaging cost and possible consumer inconvenience.

What regulatory requirements apply to the excipient strategy?

Acetaminophen OTC products must comply with the applicable FDA monograph conditions, labeling requirements, dosage limits, warnings, and manufacturing controls.[1] Excipients must be suitable for the intended route and dosage form and must not compromise the finished product’s safety, identity, strength, quality, or performance.

Key regulatory considerations include:

1. The active ingredient and strength must conform to the applicable OTC monograph.
2. The extended-release dosage form must meet applicable performance and labeling requirements.
3. Inactive ingredients must be appropriate for oral use and declared on labeling.
4. The manufacturer must establish specifications for identity, assay, impurities, dissolution, content uniformity, hardness, friability, and stability.
5. Changes in excipient supplier, grade, concentration, or processing may require comparative dissolution and stability studies.
6. Manufacturing must comply with current good manufacturing practice under 21 C.F.R. Parts 210 and 211.[3]

Acetaminophen products also require prominent liver-related warnings and dosing instructions. A formulation that improves release or swallowability cannot create a dosing pattern that encourages consumers to exceed the labeled daily limit.

What is the Orange Book and patent status of Up&Up Arthritis Pain Relief?

Up&up Arthritis Pain Relief is generally positioned as an OTC monograph product, not an FDA-approved prescription drug. Products marketed under an OTC monograph are not ordinarily protected through the same Orange Book listing and Hatch-Waxman patent-certification process used for approved prescription drugs.[4]

That distinction changes the competitive analysis:

Issue	Likely position for Up&up Arthritis Pain Relief
Orange Book listing	Generally not expected
Paragraph IV challenge	Not the principal entry mechanism
Prescription-drug exclusivity	Not applicable
Monograph compliance	Central regulatory requirement
Formulation patent risk	Possible, depending on third-party patents
Brand substitution	High relevance
Retail private-label competition	Primary commercial threat

A formulation patent could still create risk if it covers a specific modified-release matrix, coating, manufacturing process, or abuse-deterrent architecture. However, the existence of a patent would not by itself create prescription-style exclusivity for the OTC product. Freedom-to-operate analysis should cover active-ingredient combinations, extended-release acetaminophen formulations, coating systems, matrix polymers, manufacturing methods, and packaging.

How does Up&Up compare with Tylenol 8 HR Arthritis Pain?

The products compete primarily on retail price, availability, packaging, and consumer trust. The active ingredient and 650 mg extended-release positioning are broadly comparable.

Factor	Up&up Arthritis Pain Relief	Tylenol 8 HR Arthritis Pain
Commercial owner	Target private label	Kenvue
Active ingredient	Acetaminophen	Acetaminophen
Strength	650 mg extended release	650 mg extended release
Primary advantage	Lower retail price and Target availability	Brand recognition and marketing
Formulation disclosure	Label-level information	Label-level information
Patent value	Limited product-level differentiation expected	Potential historical formulation and brand-related IP
Retail strategy	Store-brand substitution	Branded premium
Main consumer barrier	Trust and brand familiarity	Higher price

The private-label manufacturer can create commercial separation through reliable dissolution, easier swallowing, better packaging, and lower cost. A direct formulation copy may have limited long-term value if the retailer’s primary objective is price competition.

What licensing and manufacturing opportunities exist?

The most relevant licensing opportunities are formulation and manufacturing technologies that improve product performance without triggering a new clinical development program.

Excipient and formulation licensing

Potential licensable technologies include:

• High-load acetaminophen direct-compression platforms
• Modified-release hypromellose matrices
• Co-processed filler-binder systems
• Low-friction oral film coatings
• Moisture-barrier coatings
• Alcohol-resistant modified-release matrices
• Taste-masking systems for liquid or chewable extensions
• Multiparticulate extended-release systems

A license is most commercially attractive when it reduces manufacturing cost, improves dissolution robustness, or supports a defensible product claim.

Contract manufacturing

Manufacturers with experience in high-dose oral solid dosage forms can compete for private-label supply agreements. Capabilities that matter include:

• Large-scale granulation
• High-speed compression
• Modified-release dissolution testing
• Automated coating
• Bottle and blister packaging
• Serialization and track-and-trace support
• Multi-site supply continuity

Retail customers are likely to value supply reliability as much as incremental formulation performance. A second-source strategy can reduce shortages and improve negotiating leverage.

What generic launch and competitive risks exist?

The product has low conventional generic-entry risk because it is itself a private-label OTC product. The main risks are substitution and price compression.

Competitive risks include:

• Other retailer private-label products
• Online marketplace brands
• Store-brand combination products
• Lower-cost acetaminophen immediate-release products
• Ibuprofen and naproxen products
• Topical diclofenac products for arthritis pain
• Branded acetaminophen products with stronger consumer recognition

Topical NSAIDs are especially relevant in the arthritis category because they offer local treatment and avoid some systemic exposure concerns associated with oral analgesics. Their use, however, depends on the indication, patient population, labeling, and consumer preference.[5]

The most credible line extensions are:

1. 100-count and 200-count value packages
2. Senior-friendly easy-open but child-resistant packaging
3. Smaller caplets
4. Single-dose blister packs
5. Travel packs
6. Liquid or chewable products for patients with swallowing difficulty
7. Acetaminophen products paired with non-drug convenience claims that remain within monograph boundaries
8. Arthritis-focused topical products sold under the same private-label architecture

Combination products require separate regulatory analysis and create additional labeling, interaction, and safety considerations.

How strong is the product’s patent and IP position?

The commercial IP position is likely moderate to weak at the product-brand level and stronger at the supplier-technology level.

IP category	Commercial assessment
Acetaminophen active ingredient	Mature and broadly unprotectable
650 mg strength	Mature dosage concept
Extended-release matrix	Potential third-party patent exposure
Excipient selection	Usually weak unless tied to unexpected performance
Manufacturing process	Potentially protectable if novel and non-obvious
Coating system	Potentially protectable
Packaging	Potentially protectable but often easy to design around
Brand and trade dress	Relevant to Target and supplier agreements
OTC monograph compliance	Regulatory requirement, not exclusivity

The strongest defensible position would usually come from a specific formulation or process that produces an unusual release profile, improved alcohol resistance, lower tablet mass, superior stability, or materially improved manufacturing yield. A generic combination of acetaminophen, cellulose, starch, lubricant, and hypromellose is unlikely to provide strong standalone patent protection.

What is the revenue opportunity?

Revenue is driven by unit volume, retailer distribution, pack size, gross margin, and repeat purchase. Public product-level revenue for Up&up Arthritis Pain Relief is generally not separately reported by Target.

A commercial model should track:

• Units sold per store per week
• Online conversion and reorder rates
• Average selling price per caplet
• Gross margin after retailer allowances
• Cost per tablet
• Packaging cost
• Return and complaint rates
• Out-of-stock frequency
• Share relative to branded acetaminophen
• Substitution from immediate-release products

Excipient optimization can improve profit through lower tablet rejection, less coating material, lower packaging weight, better line speed, and fewer stability failures. A one-cent reduction in fully loaded cost per caplet can have a material annual effect at national retail volumes, but the value depends on actual unit sales and retailer economics.

Key Takeaways

• Up&up Arthritis Pain Relief is a private-label 650 mg extended-release acetaminophen product.
• The formulation depends on a controlled-release matrix, likely using hypromellose or a similar polymer system.
• The leading excipient opportunities are smaller tablets, easier swallowing, robust dissolution, moisture protection, and lower manufacturing cost.
• OTC monograph compliance, not prescription-drug exclusivity, governs the primary regulatory strategy.
• Paragraph IV litigation and Orange Book competition are generally not the main entry issues.
• The product’s strongest commercial differentiators are price, availability, supply reliability, and consumer usability.
• Formulation patents may affect freedom to operate, particularly for modified-release matrices, coatings, and manufacturing processes.
• The most attractive licensing targets are technologies that reduce cost or improve release performance without requiring a new clinical program.

FAQs

Is Up&Up Arthritis Pain Relief the same as Tylenol Arthritis Pain?

Both products are positioned as extended-release acetaminophen products at 650 mg per caplet. Their inactive ingredients, manufacturing processes, dissolution profiles, packaging, and supplier controls may differ.

Can hypromellose be replaced in an extended-release acetaminophen tablet?

Yes, but replacement requires comparative dissolution, stability, manufacturability, and performance testing. Polymer substitution can materially change early release, total release, tablet size, and dose-dumping risk.

Does a private-label acetaminophen product need an Orange Book listing?

An OTC monograph product generally does not rely on an Orange Book listing in the same way as an approved prescription product. Compliance with the applicable OTC monograph and FDA manufacturing requirements remains necessary.

Which excipient creates the greatest commercial value?

The release-controlling polymer usually has the greatest technical impact, but the highest commercial return may come from a combination of polymer optimization, compressibility improvement, coating reduction, and packaging simplification.

Are arthritis pain relief caplets suitable for all arthritis patients?

No. The product’s labeling, contraindications, warnings, dosing limits, liver-risk warnings, and consumer-specific medical considerations govern appropriate use. Acetaminophen products also create risk when consumers use multiple medicines containing acetaminophen.

References

1. U.S. Food and Drug Administration. (2023). 21 C.F.R. Part 343: Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use. Electronic Code of Federal Regulations.

2. Target Corporation. (n.d.). Up&up Arthritis Pain Relief extended-release acetaminophen caplets, 650 mg. Target product labeling and product information.

3. U.S. Food and Drug Administration. (2024). Current good manufacturing practice, quality system regulation, and related requirements for drug products. 21 C.F.R. Parts 210 and 211.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

5. U.S. Food and Drug Administration. (2020). Voltaren Arthritis Pain gel labeling and OTC regulatory information. Center for Drug Evaluation and Research.